The Technical Analyst
Marinus Pharmaceuticals [MRNS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Marinus Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.06% $1.405
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 76.77 mill |
| EPS: | -2.63 |
| P/E: | -0.530 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 54.64 mill |
| Avg Daily Volume: | 1.749 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.530 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.09x |
| Company: PE -0.530 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.817 - 2.00 ( +/- 42.06%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-27 | Braunstein Scott | Buy | 50 000 | Common Stock |
| 2024-03-27 | Braunstein Scott | Sell | 50 000 | Stock Option (Right to Buy) |
| 2024-02-20 | Shafer Christina | Sell | 2 153 | Common Stock |
| 2024-02-20 | Manning Martha E | Sell | 1 894 | Common Stock |
| 2024-02-16 | Hulihan Joseph | Sell | 2 814 | Common Stock |
| INSIDER POWER |
|---|
| 87.45 |
| Last 96 transactions |
| Buy: 2 669 285 | Sell: 293 774 |
Forecast:
16:00 - $1.405
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.405
Forecast 2: 16:00 - $1.405
Forecast 3: 16:00 - $1.405
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.405 (-1.06% ) |
| Volume | 1.130 mill |
| Avg. Vol. | 1.749 mill |
| % of Avg. Vol | 64.59 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MRNS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $9.97 | N/A | Active |
|---|
MRNS
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Latest Press Releases
2024-04-25 17:30:00 - Press Release
Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Marinus Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 25, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of marinus pharmaceuticals, inc. ("marinus" or "the company") (nasdaq:mrns) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-04-22 05:00:00 - Press Release
Marinus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky To Discuss Your Rights - Mrns
New york, ny / accesswire / april 22, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of marinus pharmaceuticals, inc. ("marinus pharmaceuticals, inc.") (nasdaq:mrns) concerning possible violations of federal securities laws. on april 15, 2024, marinus announced that "an independent data monitoring committee (dmc) has recommended continuing the pivotal phase 3 raise trial evaluating intravenous (iv) ganaxolone for the treatment of refractory status epilepticus (rse) following an interim analysis.
2024-04-22 04:00:00 - Press Release
Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Marinus Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 22, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of marinus pharmaceuticals, inc. ("marinus" or "the company") (nasdaq:mrns) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-04-21 08:00:00 - Press Release
Investors Who Lost Money On Marinus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky About An Ongoing Investigation - Mrns
New york, ny / accesswire / april 21, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of marinus pharmaceuticals, inc. ("marinus pharmaceuticals, inc.") (nasdaq:mrns) concerning possible violations of federal securities laws. on april 15, 2024, marinus announced that "an independent data monitoring committee (dmc) has recommended continuing the pivotal phase 3 raise trial evaluating intravenous (iv) ganaxolone for the treatment of refractory status epilepticus (rse) following an interim analysis.
2024-04-21 06:00:00 - Press Release
Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Marinus Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 21, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of marinus pharmaceuticals, inc. ("marinus" or "the company") (nasdaq: mrns) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Latest News
2024-04-16 12:51:08 - Zacks Investment Research
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.
2024-04-15 12:54:18 - InvestorPlace
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.
2024-04-15 12:06:18 - InvestorPlace
Why Are Stocks Up Today?
Stocks are up today and investors wondering what's behind that rally have come to the right place as we have the latest news for Monday! Stocks are up today as retail data came in better than expected.
2024-04-15 11:30:59 - InvestorPlace
Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?
Marinus Pharmaceuticals (NASDAQ: MRNS ) stock is taking a beating on Monday after the pharmaceutical company announced results from a Phase 3 clinical trial. It's bad news for MRNS stockholders today as the Phase 3 trail of intravenous ganaxolone as a treatment for refractory status epilepticus (RSE) failed to meet expectations.
2024-03-05 21:29:12 - Seeking Alpha
Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call Transcript
Start Time: 16:30 End Time: 17:36 March 1, 0000 ET Q4 2023 Earnings Conference Call March 05, 2024, 16:30 PM ET
2024-03-05 18:11:08 - Zacks Investment Research
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.76 per share a year ago.
2024-01-22 11:00:16 - Zacks Investment Research
Should You Add Marinus (MRNS) Stock to Your Portfolio Now?
Here, we discuss some reasons why investing in Marinus Pharmaceuticals' (MRNS) stock may turn out to be a prudent move.
2023-11-07 14:00:06 - Seeking Alpha
Marinus Pharmaceuticals, Inc. (MRNS) Q3 2023 Earnings Call Transcript
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Sonya Weigle - SVP, IR Scott Braunstein - CEO, President & Chairman Christina Shafer - Chief Commercial Officer Joseph Hulihan - Chief Medical Officer Steven Pfanstiel - COO, CFO & Treasurer Thomas Lyons - Chief Business Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Joseph Thome - TD Cowen Joon Lee - Truist Securities Andrew Tsai - Jefferies Marc Goodman - Leerink Partners Charles Duncan - Cantor Fitzgerald & Co. Douglas Tsao - H.C. Wainwright & Co. Operator Greetings and welcome to the Marinus Pharmaceuticals' Third Quarter 2023 Financial Results and Business Update Call.
2023-10-24 07:01:00 - Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023
RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on November 7, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on November 7, 2023. Participants may access the conference call via webcast on the Investors and Media page of Marinus'.
2023-09-21 16:00:00 - Business Wire
Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the 2023 Cantor Global Healthcare Conference. The fireside chat will take place on Thursday, September 28 beginning at 10:55 a.m. Eastern Time. A link to the event can be accessed on the.